Cigna Group stock holds gains as valuation debate intensifies

Published on 09/16/2026 at 12:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cigna Group stock is trading around USD 288.90 as of September 16, 2026, while several valuation models point to a fair value well above the current level. Recent earnings and dividend metrics underline the health services provider’s cash generation and shareholder returns.

Modernes Bürogebäude eines US-Krankenversicherers mit Glasfassade und gepflegtem Außengelände — Cigna Group Krankenversicherung modernes Unternehmensgebäude mit Glasfassade, ISIN US1255231003, Mitarbeiter gehen zum Eingang, Illustration mit AI erstellt.

Cigna Group stock (ISIN US1255231003) is trading around USD 288.90 as of September 16, 2026 on the New York Stock Exchange, while multiple valuation approaches suggest a significantly higher fair value for the health services provider.

Valuation models see upside

According to Simply Wall St on September 16, 2026, one prominent valuation narrative pegs Cigna Group’s fair value at about USD 636 per share compared with a latest close of USD 288.90, implying the stock is more than 100 percent below that modelled estimate.

The same analysis cites an alternative fair value of roughly USD 427.89 per share, which still places Cigna Group stock around 32 percent below that calculated level based on the current trading price of USD 288.90 on September 16, 2026.

Earnings and dividend support the story

Cigna Group last reported quarterly earnings on July 30, 2026 for a recent reporting period, delivering earnings per share of USD 7.78 compared with consensus expectations of USD 7.60, a beat of USD 0.18 per share according to MarketBeat.

In that same quarter, the company generated revenue of USD 70.04 billion versus analyst estimates of USD 70.14 billion, and revenue was up 6.7 percent year over year compared with the same quarter in the prior year when it posted USD 7.20 earnings per share, highlighting steady top line growth in the health services business as reported by MarketBeat.

For full-year 2026, Cigna Group has set guidance for earnings per share at about USD 30.45 on an adjusted basis and research analysts currently anticipate EPS of roughly USD 30.51 for the year, underscoring management’s confidence in sustained profit generation according to MarketBeat.

The company also supports shareholder returns through a regular dividend; Cigna Group recently disclosed a quarterly dividend of USD 1.56 per share, translating into an annualized payout of USD 6.24 and a dividend yield of around 2.2 percent at prevailing prices, with a dividend payout ratio of 25.82 percent that leaves room for reinvestment and future increases as detailed by MarketBeat.

Capital allocation and market perception

Capital allocation has been another lever for Cigna Group, with the company using share repurchases to return capital to shareholders and manage its equity base; in 2025 it repurchased about 11.9 million shares of common stock for roughly USD 3.6 billion, and in the second quarter of 2026 it repurchased approximately 900,000 shares for around USD 250 million following a pause in buybacks in the first quarter, according to comments by CFO Ann Dennison reported by Becker's Payer on September 15, 2026.

From a market sentiment perspective, data compiled by MarketBeat indicate that Cigna Group currently carries a consensus rating of Moderate Buy from covering analysts, with an average target price of USD 337.10 per share, suggesting upside of roughly 16.7 percent relative to the latest trading level of about USD 288.90 as of September 16, 2026.

At the same time, valuation-focused research on dividend sustainability notes that Cigna Group appears about 25.9 percent undervalued relative to a GF Value metric, while emphasizing the resilience of its dividend profile, as highlighted in a recent analysis by GuruFocus on September 15, 2026.

Risks behind the undervaluation thesis

The valuation gap identified by several models is partly tempered by the risks inherent in Cigna Group’s business, including exposure to medical cost inflation, regulatory changes in US healthcare policy, and competitive dynamics in health insurance and pharmacy benefit management, as discussed in a broader risk-focused piece on whether Cigna Group is still undervalued by Yahoo Finance Canada dated September 16, 2026.

For investors, the key question is whether current guidance and capital return plans will continue to offset these risks; with EPS for the latest quarter up from USD 7.20 a year earlier to USD 7.78 and revenue up 6.7 percent year over year, Cigna Group has recently shown it can grow profits faster than sales, a combination that often supports higher valuation multiples when sustained, as illustrated by the recent earnings data from MarketBeat.

Cigna Group stock price snapshot

Cigna Group stock most recently closed around USD 288.90 on the New York Stock Exchange, and at that level the shares trade below several published fair value estimates and roughly 16.7 percent under the average analyst target of USD 337.10 as of September 16, 2026, while continuing to offer a dividend yield of about 2.2 percent backed by a payout ratio of 25.82 percent.